Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Cetuximab + Encorafenib & Colorectal Cancer (CRC) (BRAF m), Cetuximab + encorafenib is approved by both the FDA and EMA for adults with Colorectal Cancer (CRC) (BRAF m) who have received prior systemic therapy; more recently, combinations with mFOLFOX6 have also gained first‑line approval, but the core targeted doublet remains encorafenib + cetuximab (1, 2, 3, 4)
The randomized clinical phase III trial, known as NCT02928224 (BEACON CRC), demonstrated that the combination of [Cetuximab + Encorafenib](b…